Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats.

Russo A, Castiglione F, Salonia A, Benigni F, Rigatti P, Montorsi F, Andersson KE, Hedlund P

European urology21 Dec 2010Cited by 17 (Europe PMC)

PMID21196074DOI10.1016/j.eururo.2010.12.007PepBankPUB-21196074

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In female rats, systemic ganirelix lowered luteinising hormone compared with controls.
In plain wordsIn rats, systemic ganirelix lowered luteinising hormone compared with controls.
Peptide
Ganirelix
Outcome
DecreaseLuteinising hormone
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
Luteinising hormone levels were lower in rats treated systemically with ganirelix than in controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607401
02AnimalAnimal study (in vivo)Efficacy outcome
In female rats, body weight did not differ between systemic ganirelix and controls.
In plain wordsIn rats, body weight did not differ between systemic ganirelix and controls.
Peptide
Ganirelix
Outcome
No significant changeBody weight
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Body weight · Metabolic and weight
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
No differences were observed in body or bladder weights.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607402
03AnimalAnimal study (in vivo)Efficacy outcome
In female rats, bladder weight did not differ between systemic ganirelix and controls.
In plain wordsIn rats, bladder weight did not differ between systemic ganirelix and controls.
Peptide
Ganirelix
Outcome
No significant changeBladder weight
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
No differences were observed in body or bladder weights.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607403
04AnimalAnimal study (in vivo)Efficacy outcome
In female rats, baseline micturition interval was similar with systemic ganirelix and controls.
In plain wordsIn rats, baseline time between urinations was similar with systemic ganirelix and controls.
Peptide
Ganirelix
Outcome
No significant changeBaseline micturition interval
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
Micturition interval (MI), micturition volume (MV), residual volume, and bladder capacity (BC) were similar in both groups at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607404
05AnimalAnimal study (in vivo)Efficacy outcome
In female rats, baseline micturition volume was similar with systemic ganirelix and controls.
In plain wordsIn rats, baseline urine volume per urination was similar with systemic ganirelix and controls.
Peptide
Ganirelix
Outcome
No significant changeBaseline micturition volume
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
Micturition interval (MI), micturition volume (MV), residual volume, and bladder capacity (BC) were similar in both groups at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607405
06AnimalAnimal study (in vivo)Efficacy outcome
In female rats, baseline residual volume was similar with systemic ganirelix and controls.
In plain wordsIn rats, baseline residual urine volume was similar with systemic ganirelix and controls.
Peptide
Ganirelix
Outcome
No significant changeBaseline residual volume
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
Micturition interval (MI), micturition volume (MV), residual volume, and bladder capacity (BC) were similar in both groups at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607406
07AnimalAnimal study (in vivo)Efficacy outcome
In female rats, baseline bladder capacity was similar with systemic ganirelix and controls.
In plain wordsIn rats, baseline bladder capacity was similar with systemic ganirelix and controls.
Peptide
Ganirelix
Outcome
No significant changeBaseline bladder capacity
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
Micturition interval (MI), micturition volume (MV), residual volume, and bladder capacity (BC) were similar in both groups at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607407
08AnimalAnimal study (in vivo)Efficacy outcome
In female rats, baseline urodynamic pressure parameters did not differ between systemic ganirelix and controls.
In plain wordsIn rats, baseline bladder pressure measures did not differ between systemic ganirelix and controls.
Peptide
Ganirelix
Outcome
No significant changeBaseline urodynamic pressure parameters
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Source sentences
Summary
No differences in urodynamic pressure parameters were observed between groups at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607408
09AnimalAnimal study (in vivo)Efficacy outcome
In female rats, systemic ganirelix attenuated the prostaglandin-induced reduction in micturition interval compared with controls.
In plain wordsIn rats, systemic ganirelix limited the prostaglandin-induced shortening of time between urinations compared with controls.
Peptide
Ganirelix
Outcome
IncreaseMicturition interval during prostaglandin challenge
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Measurements
Micturition interval reduction
22%
ganirelix mean
Micturition interval reduction variability
3%
ganirelix reported plus/minus
Micturition interval reduction
43%
control mean
Micturition interval reduction variability
4%
control reported plus/minus
Source sentences
Summary
MI, MV, and BC were reduced by 43%±4%, 50%±4%, and 43%±4% (controls) versus 22%±3%, 23%±3%, and 21%±3% (ganirelix-treated rats; p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Intravesical prostaglandin E(2) reduced MI, MV, and BC, and it increased basal pressure (BP), threshold pressure (TP), flow pressure (FP), and maximum pressure (MP) in all rats.
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607409
10AnimalAnimal study (in vivo)Efficacy outcome
In female rats, systemic ganirelix attenuated the prostaglandin-induced reduction in micturition volume compared with controls.
In plain wordsIn rats, systemic ganirelix limited the prostaglandin-induced reduction in urine volume per urination compared with controls.
Peptide
Ganirelix
Outcome
IncreaseMicturition volume during prostaglandin challenge
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Measurements
Micturition volume reduction
23%
ganirelix mean
Micturition volume reduction variability
3%
ganirelix reported plus/minus
Micturition volume reduction
50%
control mean
Micturition volume reduction variability
4%
control reported plus/minus
Source sentences
Summary
MI, MV, and BC were reduced by 43%±4%, 50%±4%, and 43%±4% (controls) versus 22%±3%, 23%±3%, and 21%±3% (ganirelix-treated rats; p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Intravesical prostaglandin E(2) reduced MI, MV, and BC, and it increased basal pressure (BP), threshold pressure (TP), flow pressure (FP), and maximum pressure (MP) in all rats.
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607410
11AnimalAnimal study (in vivo)Efficacy outcome
In female rats, systemic ganirelix attenuated the prostaglandin-induced reduction in bladder capacity compared with controls.
In plain wordsIn rats, systemic ganirelix limited the prostaglandin-induced reduction in bladder capacity compared with controls.
Peptide
Ganirelix
Outcome
IncreaseBladder capacity during prostaglandin challenge
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Measurements
Bladder capacity reduction
21%
ganirelix mean
Bladder capacity reduction variability
3%
ganirelix reported plus/minus
Bladder capacity reduction
43%
control mean
Bladder capacity reduction variability
4%
control reported plus/minus
Source sentences
Summary
MI, MV, and BC were reduced by 43%±4%, 50%±4%, and 43%±4% (controls) versus 22%±3%, 23%±3%, and 21%±3% (ganirelix-treated rats; p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Intravesical prostaglandin E(2) reduced MI, MV, and BC, and it increased basal pressure (BP), threshold pressure (TP), flow pressure (FP), and maximum pressure (MP) in all rats.
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607411
12AnimalAnimal study (in vivo)Efficacy outcome
In female rats, systemic ganirelix attenuated the prostaglandin-induced threshold pressure increase compared with controls.
In plain wordsIn rats, systemic ganirelix limited the prostaglandin-induced rise in threshold pressure compared with controls.
Peptide
Ganirelix
Outcome
DecreaseProstaglandin-induced threshold pressure increase
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Measurements
Threshold pressure increase
16%
ganirelix mean
Threshold pressure increase variability
7%
ganirelix reported plus/minus
Threshold pressure increase
38%
control mean
Threshold pressure increase variability
8%
control reported plus/minus
Source sentences
Summary
TP and FP increased by 38%±8% and 30%±4% (controls) versus 16%±7% and 16%±5% (ganirelix; p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Intravesical prostaglandin E(2) reduced MI, MV, and BC, and it increased basal pressure (BP), threshold pressure (TP), flow pressure (FP), and maximum pressure (MP) in all rats.
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607412
13AnimalAnimal study (in vivo)Efficacy outcome
In female rats, systemic ganirelix attenuated the prostaglandin-induced flow pressure increase compared with controls.
In plain wordsIn rats, systemic ganirelix limited the prostaglandin-induced rise in flow pressure compared with controls.
Peptide
Ganirelix
Outcome
DecreaseProstaglandin-induced flow pressure increase
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Measurements
Flow pressure increase
16%
ganirelix mean
Flow pressure increase variability
5%
ganirelix reported plus/minus
Flow pressure increase
30%
control mean
Flow pressure increase variability
4%
control reported plus/minus
Source sentences
Summary
TP and FP increased by 38%±8% and 30%±4% (controls) versus 16%±7% and 16%±5% (ganirelix; p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Intravesical prostaglandin E(2) reduced MI, MV, and BC, and it increased basal pressure (BP), threshold pressure (TP), flow pressure (FP), and maximum pressure (MP) in all rats.
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607413
14AnimalAnimal study (in vivo)Efficacy outcome
In detrusor tissue from systemically treated rats, ganirelix increased carbachol contraction force compared with controls.
In plain wordsIn rats, detrusor tissue after systemic ganirelix treatment contracted more strongly to carbachol than control tissue.
Peptide
Ganirelix
Outcome
IncreaseCarbachol-induced detrusor contraction force
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg/kg daily · systemic · 2 weeksAs given in this study (rat).
Measurements
Carbachol contraction force
231%
ganirelix, relative to K+-induced contractions
Carbachol contraction force
177%
controls, relative to K+-induced contractions
Source sentences
Summary
The maximal force of contractions for carbachol was larger in detrusor from ganirelix-treated rats (231% vs 177% of 60 mM K+-induced contractions).
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607414
15AnimalAnimal study (in vivo)Efficacy outcome
In female rats, intravesical ganirelix increased micturition interval, micturition volume, and bladder capacity and decreased basal, threshold, flow, and maximum pressures, with an ambiguous effective dose.
In plain wordsIn rats, intravesical ganirelix increased urination intervals, urine volume, and bladder capacity and lowered four bladder pressures, with an unclear effective dose.
Peptide
Ganirelix
Outcome
MixedIntravesical micturition and pressure response
Study
ratn: not reported in source
Female Sprague-Dawley rats
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated · intravesical · acuteAs given in this study (rat).
Source sentences
Summary
At 0.14 mg/l, but not 0.14 mg/l, IVES ganirelix increased MI, MV, and BC and decreased BP, TP, FP, and MP.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607415
16LabEx vivo tissueEfficacy outcome
In rat detrusor tissue in vitro, ganirelix had no effect on detrusor function.
In plain wordsIn lab tests, ganirelix did not affect rat detrusor function.
Peptide
Ganirelix
Outcome
No significant changeIn-vitro detrusor function
Study
ratn: not reported in source
Rat detrusor tissue
Comparator
Vehicle controls
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
In vitro, ganirelix had no effect on detrusor function.
1 context sentence(design, population, supporting numbers)
Summary · context
Female Sprague-Dawley rats received 2 wk of daily systemic (0.1 mg/kg) or acute intravesical administration (IVES; 0.14 mg/l or 1.4 mg/l) ganirelix or vehicle (controls).
Report a problemFND-2119607416

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats.

Summary

Results from this study16

Version history

Subjects

Publication types

MeSH terms